Virpax Pharmaceuticals, Inc. (VRPX)
OTCMKTS · Delayed Price · Currency is USD
0.0110
0.00 (0.00%)
Jul 31, 2025, 8:00 PM EDT

Virpax Pharmaceuticals Company Description

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders.

Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

The company’s preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.

Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Virpax Pharmaceuticals, Inc.
CountryUnited States
Founded2016
IndustryBiotechnology
SectorHealthcare
Employees2
CEOJatinder Dhaliwal

Contact Details

Address:
1055 Westlakes Drive
Berwyn, Delaware 19312
United States
Phone610 727 4597
Websitevirpaxpharma.com

Stock Details

Ticker SymbolVRPX
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS9282511073
SIC Code2834

Key Executives

NamePosition
Jatinder DhaliwalChief Executive Officer and Chairman
Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.Chief Scientific Officer